NaviHealth, for example, has partnered with 11 hospitals to take financial responsibility for episodes of care under BPCI
Model 2--the most comprehensive model stretching from three days before admission to 90 days after discharge.
Physicians practicing care that considers quality, cost, and outcomes will be essential contributors to success under bundled payment models like BPCI
Further, the BPCI
Act establishes, in most instances, a rather complex set of disclosures and counterdisclosures of patent information between the owner of a reference product and a biosimilar applicant--that process alone adds up to a 200-day timetable.
FDA held a 2-day public hearing in November 2010, to obtain input from interested stakeholders on specific issues and challenges associated with the implementation of the BPCI
On April 10, the BPCI
relented and said that: "After due deliberation, we have reassessed the situation pertaining to Miss Maria Venus Raj and have decided, for humanitarian reasons, that if she is able to obtain a valid Philippine passport, we will reinstate her as the reigning Bb Pilipinas-Universe.
has done for a number of years is negotiate for better benefits and underwriting concessions for disability, life, and accident insurance, as well as long-term care and other coverages.
naviHealth's partnerships will operate under Model 2 of the BPCI
But in a statement yesterday BPCI
said: "We have reassessed the situation pertaining to Miss Maria Venus Raj and have decided, for humanitarian reasons, that if she is able to obtain a valid Philippine passport, we will reinstate her as the reigning Bb Pilipinas-Universe.
Bundled Payments for Care Improvement In April 2015, Genesis HealthCare entered the BPCI
initiative as the Model 3 Awardee Convener of 32 episode-initiating entities.
A special bundled payment panel focused on Medicare BPCI
implementation and attracting private pay bundles
De Lima also said that BPCI
had not clarified their basis for recalling Raj's title.
She also serves on FDA's Biosimilars Implementation Committee (BIC) and as an FDA panel member for public meetings on the implementation of the BPCI
Act; members of her staff serve on the agency's Biosimilars Review Committee (BRC).